Sun, 19 Apr 2015
KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy...
A strong and growing dividend can be a great signal of a quality stock for any kind of investor.
Morningstar's director of personal finance recommends locking down short-term income needs in cash-like investments, stress-testing your bond holdings, and staying poised to buy on the dips.
Several names have great dividend-growth potential, while industry tailwinds will be a boon for another, according to Sanibel Captiva's Pat Dorsey .
Morningstar markets editor Jeremy Glaser highlights some must-dos in 2013 for banks, Blackberry devices, frazzled investors, and corporate America's balance sheets.
News this week showed market players paying up for media assets, paying out for tax relief, and more.
2012 shows the importance of paying attention to valuations amid the doom-and-gloom headlines.
Morningstar markets editor Jeremy Glaser unpacks the week's M&A news and consumer data to see who's in a buying mood.
Investors should keep their expectations in check with few asset classes looking particularly attractive and complacency in the marketplace, says Allocation Fund Manager of the Year David Giroux of T. Rowe Price Capital Appreciation.
©2014 Morningstar Advisor. All right reserved.